← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $169B	2,391	-13	-0.5%	$173B
2	2 Amgen AMGN $237B	1,887	-5	-0.3%	$91.1B
3	3 Eli Lilly LLY $1.14T	1,605	+44	+3%	$102B
4	4 Becton Dickinson BDX $52.8B	1,382	+36	+3%	$57.9B
5	5 McKesson MCK $117B	856	0	0%	$19.7B
6	6 Regeneron Pharmaceuticals REGN $82.2B	719	+48	+7%	$30.4B
7	7 Conagra Brands CAG $6.87B	702	-3	-0.4%	$12.1B
8	8 Lamb Weston LW $7.41B	645	+30	+5%	$9.64B
9	9 Novo Nordisk NVO $173B	580	+30	+5%	$9.19B
10	10 AstraZeneca AZN $259B	562	+4	+0.7%	$19.4B
11	11 Teva Pharmaceutical Industries Limited TEVA $48.3B	522	-30	-5%	$10.5B
12	12 ResMed RMD $33.9B	478	-24	-5%	$10.2B
13	13 DaVita DVA $12.1B	440	-11	-2%	$8.04B
14	14 West Pharmaceutical WST $27.1B	379	+24	+7%	$7.51B
15	15 DELISTED CATALENT, INC. CTLT	283	+16	+6%	$6.02B
16	16 Herbalife HLF $1.55B	269	+16	+6%	$7.7B
17	17 Medifast MED $137M	246	-1	-0.4%	$1.53B
18	18 DELISTED WW International WW	209	-61	-23%	$1.16B
19	19 Opko Health OPK $1.2B	201	-1	-0.5%	$419M
20	20 Tootsie Roll Industries TR $2.9B	188	+10	+6%	$583M
21	21 Accendra Health ACH $21.2M	187	-23	-11%	$235M
22	ARNA 22 DELISTED Arena Pharmaceuticals Inc ARNA	184	+7	+4%	$1.88B
23	23 Fresenius Medical Care FMS $11.9B	182	-15	-8%	$363M
24	24 Viking Therapeutics VKTX $3.33B	165	-3	-2%	$456M
25	TWNK 25 DELISTED Hostess Brands, Inc. Class A Common Stock TWNK	155	+10	+7%	$1.4B